Keywords
Small bowel endoscopy - Laparoscopy
Introduction
First described by Peutz in 1921 [1] and Jegher in 1949 [2], Peutz-Jeghers Syndrome (PJS) is an autosomal-dominant genetic disorder affecting
1 in 120,000 births [3]. It is characterized by the formation of hamartomatous polyps in the gastrointestinal
tract and mucocutaneous melanin pigmentation. When compared with the general population,
patients with PJS carry a significantly increased risk for the development of malignancies,
particularly of the breast and pancreas. This risk has been reported to be as high
as 93% for developing any cancer by the age of 64 while the average lifetime risks
of colorectal, gastric and small-bowel cancer are 39%, 29%, and 13% respectively [3]
[4].
A diagnosis of PJS is made by either: ≥ 2 confirmed PJS-type hamartomatous polyps;
or any number of PJS-type polyps in a patient with characteristic mucocutaneous pigmentation
or family history of PJS in a close relative; or characteristic mucocutaneous pigmentation
combined with a family history of PJS in a close relative [5]. Histopathologically, PJS-associated hamartomas are characterized by interdigitating
smooth muscle bundles in a characteristic arborizing “branching tree” or “christmas-tree”
like appearance throughout their lamina propria and lobular organization of mucosal
crypts [6]. PJS should also be considered in males with gynecomastia secondary to estrogen-producing
Sertoli cell testicular tumors and in individuals with an unexplained history of intussusception
as a child or young adult.
Intestinal hamartomas frequently cause intussusception or hemorrhage [7]. Management of these adverse events (AEs) typically requires repeated emergency
surgery leading to sequela such as short gut and small-bowel obstruction from adhesions
[2]. Given the prevalence of these AEs, surveillance and preemptive resection of intestinal
hamartomas has been suggested as intervention to reduce morbidity and mortality in
this patient population. In 1995, intraoperative enteroscopy (IOE) was widely accepted
as the gold standard method to manage PJS patients based on the observation of the
decrease in adverse events and a surveillance program published in the British Journal
of Surgery in 1995 recommended IOE for removal of small-bowel polyps in patients with
PJS [8].
However, data published to date is inadequate to promote guideline recommendations
in favor of device-assisted enteroscopy (DAE) for prophylactic removal of hamartomas.
Guidelines for surveillance of gastrointestinal hamartomas in PJS have been published
and recommend evaluation by upper gastrointestinal endoscopy, colonoscopy, and video
capsule endoscopy every 2 to 3 years after age 18 [3]
[9]
[10].
The development of video capsule endoscopy (VCE) and DAE in 2001 revolutionized the
diagnostic and therapeutic capabilities of endoscopy in the management of small-bowel
pathology, including PJS [11]. With the progressive adoption of DAE, the deep small bowel can now be accessed
for endoscopic polypectomy. Emergent surgery is commonly required in PJS patients
for management of AEs associated with hamartomas. Forty-four percent of patients with
PJS require laparotomy by the age 10 and 40% of patients who require an initial laparotomy
require a repeat laparotomy within 5 years [12]. We hypothesized that DAE is effective and safe for small-bowel monitoring and prophylactic
removal of small-bowel hamartomas in patients with PJS with a goal of reducing the
incidence of emergent surgery related to small-bowel hamartomas.
Patients and methods
Study design
We conducted a retrospective study in three US high-volume referral centers for DAE:
Louisiana State University Health Sciences Center, New Orleans, Louisiana, United
States; Duke University Medical Center, Durham, North Carolina, United States, and
University of Massachusetts Medical Center, Worcester, Massachusetts, United States.
These sites care for a broad and diverse group of patients across a wide geographic
section of the United States. The endoscopists who performed the DAEs were all highly
experienced having each performed > 200 DAE exams. All of the participating centers
obtained approval from their respective institutional review boards prior to study
initiation. Using endoscopy reporting software as a database (Provation: Minneapolis-St.
Paul, Minnesota, United States), we identified all adult patients who underwent DAE
during the investigational period. We then conducted a medical record chart review
to analyze data on all DAEs performed in patients with PJS. Double-balloon enteroscopy
(DBE) was the most commonly utilized DAE technique. Using a REDCap (Research Electronic
Data Capture) database, we recorded information related to the patient population
and endpoints across the three centers. At the end of the study period, patients were
contacted via telephone to obtain longitudinal data regarding any laparotomies or
PJS related adverse events experienced after initial DAE.
Polypectomy
DAE was pursued with a goal of clearing the small bowel of all hamartomas > 10 mm
in size. Polypectomy was commonly performed through endoscopic mucosal resection involving
submucosal saline injection followed by hot snare resection, this technique was used
to separate the stalk of the polyp from the intestinal wall to avoid bowel injury
during polypectomy. The use of hemostatic clips and/or detachable snares were performed,
and use was based upon physician preference and performed on a case-by-case basis.
None of our patients experienced clinically significant bleeding after polypectomy.
European Society of Gastrointestinal Endoscopy guidelines recommend elective polypectomy
for small-bowel hamartomas starting at 15 mm [13]. However, our three centers independently arrived at the threshold of 10 mm for
polypectomy. This was based upon previous studies in the literature using 10 mm as
a minimum that showed a significant decrease in the need for polyp-related emergent
surgery [14]
[15]
[16]. As hamartomas grow in size, the serosa invaginates into the stalk of the polyp
resulting in increased risk of perforation during polypectomy. In addition, the risk
of malignant potential associated with hamartomas correlates with a size > 10 mm [17].
Patient population and data points
Adult patients (aged > 18 years) with a clinical diagnosis of PJS who underwent DAE
between January 2007 and January 2020 were included in this study whereas longitudinal
data were collected until May 2022. Using the REDCap database, we recorded patient
characteristics including age, gender, use of antithrombotics, previous history of
DAE, and previous history of laparotomy; DAE characteristics including approach, technique,
and procedure time; size, location, and number of endoscopically resected small-bowel
hamartomas; and AEs. In our study, major AEs were defined as perforation, pancreatitis,
excessive bleeding, and any AE requiring hospitalization or emergent surgery.
Results
Patients
Twenty-three patients met inclusion criteria across the three centers: LSU New Orleans
(n = 10), UMass (n = 10), and Duke (n = 3) between 2007 and 2020. Patient ages ranged
from 15 to 59 with a mean age of 32 at index surveillance DAE. The majority of subjects
(63%) were female. None of the patients had undergone DAE prior to the study period.
Prior to index surveillance DAE, all patients had a clinical diagnosis of PJS and
all had undergone VCE and/or cross-sectional imaging with computed tomography or magnetic
resonance imaging confirming the presence of small-bowel polyps. The average interval
between index surveillance DAE and repeat surveillance DAE was 2.5 years. Patient
characteristics are shown in [Table 1].
Table 1 Patient characteristics.
|
All patients (N=23)
|
PJS, Peutz-Jeghers syndrome.
|
Gender
|
|
14
|
|
9
|
Antithrombotics
|
None
|
Manifestations of PJS
|
|
6
|
|
23
|
|
1
|
Laparotomy prior to enrollment %
|
75
|
DAE data points
A total of 46 DAE exams were performed, 33 by an anterograde (oral) and 13 by a retrograde
(rectal) approach. The preferred initial route was anterograde enteroscopy after review
of imaging as the burden of hamartomas was more prevelant in the proximal small bowel
in our patient population. Retrograde DAE was not necessary in cases in which anterograde
DAE was successful in examining the entire small bowel (total enteroscopy). Anterograde
and retrograde procedures were performed on separate days due to length of each procedure
time. Endoscopic polypectomy was performed in 87% of these exams with a goal of removing
all hamartomas > 10 mm. All 23 patients were observed to have gastric polyps that
were not removed. Of the 13 retrograde enteroscopies, four patients had < 10-mm polyps
removed that were confirmed as adenomatous by histology. The average number of polypectomies
performed per procedure was 2.85. The average size of resected hamartomas was 15.2
mm with a mean polyp size of 18.4 mm in the jejunum (median, interquartile range [IQR]
19, range 15–25), 15.7 mm in the ileum (median, IQR 17, range 15–20), and 10.9 mm
in the duodenum (median, IQR 12, range 11–13). Additional information regarding data
points for all 23 patients is shown in [Table 2]. Data from all our patients are shown in [Table 3].
Table 2 DAE data.
|
Total procedures (N= 46)
|
DAE, device-assisted enteroscopy; IQR, interquartile range.
|
DAE
|
46
|
Anterograde
|
33
|
Retrograde
|
13
|
No. of polypectomies
|
131
|
Size of polypectomies (mm)
|
Median (IQR)
|
|
12 (11–13)
|
|
19 (15–25)
|
|
17 (15–20)
|
Adverse events
|
2
|
Average time to follow up in years
|
2.5
|
Number of surgeries after enrollment
|
2
|
Table 3 Cohort surveillance data.
Patient
|
Gender
|
Polypectomies
|
Polyp location
|
Complications
|
Observation time (years)
|
D, duodenum; J, jejunum; I, ileum.
|
1
|
Male
|
4
|
D, J
|
None
|
16
|
2
|
Female
|
6
|
J
|
Serositis
|
16
|
3
|
Male
|
3
|
J
|
None
|
9
|
4
|
Female
|
12
|
D, J
|
None
|
16
|
5
|
Female
|
4
|
I
|
Perforation
|
16
|
6
|
Female
|
4
|
J
|
None
|
16
|
7
|
Female
|
3
|
I
|
None
|
14
|
8
|
Female
|
14
|
J, I
|
None
|
16
|
9
|
Male
|
7
|
J
|
None
|
16
|
10
|
Male
|
2
|
I
|
None
|
10
|
11
|
Female
|
12
|
D, J, I
|
None
|
16
|
12
|
Male
|
8
|
J
|
None
|
15
|
13
|
Female
|
3
|
J
|
None
|
16
|
14
|
Female
|
3
|
J, I
|
None
|
7
|
15
|
Female
|
11
|
D, J
|
None
|
16
|
16
|
Female
|
7
|
J
|
None
|
16
|
17
|
Female
|
5
|
J
|
None
|
16
|
18
|
Male
|
6
|
D, J
|
None
|
13
|
19
|
Female
|
3
|
D, J
|
None
|
16
|
20
|
Female
|
4
|
I
|
None
|
16
|
21
|
Male
|
5
|
J
|
None
|
16
|
22
|
Male
|
2
|
J
|
None
|
12
|
23
|
Male
|
3
|
J
|
None
|
16
|
Adverse events
Two AEs occurred in 131 small-bowel polypectomies. One perforation occurred following
removal of a 10-mm hamartoma with a thin stalk (3 mm) using hot snare without saline-lift.
We theorized that lack of a cushion of fluid to absorb the electrical current was
a risk factor for transmural injury in this case. A second patient developed post-polypectomy
(serositis) syndrome which led to a 48-hour hospitalization for observation. No additional
AEs were discovered by electronic medical record review of all patients or follow-up
phone interview of 17 patients.
Rate of laparotomy
Eighteen patients (75%) had undergone one or more emergent lapartomies for small-bowel
hamartomas prior to index surveillance DAE. The incidence of these surgeries was fairly
consistent after age 5 ([Fig. 1]).
Following index surveillance DAE, only one emergent laparotomy was required across
366 years of combined patient follow-up. This patient required emergent surgery for
perforation as an AE of hot snare resection of a jejunal hamartoma as described above.
She recovered from this surgery and was discharged 4 days after admission. A second
patient required elective laparotomy for removal of a large hamartoma which could
not be reached by DAE. No additional laparotomies were found upon follow-up interview
and medical record review for all patients.
Fig. 1 Incidence of surgeries in cohort by age.
Discussion
Our study suggests that DAE is safe and effective in removing hamartomas from the
small bowel to prevent future AEs and need for emergent laparotomy. Historical data
have shown that patients with PJS commonly require repeated emergent surgery related
to intestinal hamartomas. In one study, 68% of patients with PJS had undergone an
emergent laparotomy for intussusception related to small-bowel hamartomas by age 18
years and the majority of these patients required a second laparotomy within 5 years
of initial surgery. In 20 patients interviewed between 1943 and 1987 at St. Mark’s
Hospital in London, 12 had repeat laparotomies within 10 years of their first surgery
and four of those occurred the first year. In a cohort study including 110 PJS patients,
69% developed at least one intussusception leading to surgery at a median age of 16
years [18]
[19].
If surgery is required, elective surgery is preferred over emergent surgery. Historical
data have shown that 70% of laparotomies performed for intestinal hamartomas are emergency
interventions [5]. IOE has been studied to perform a “clean sweep” of all significant hamartomas from
the small bowel and has been demonstrated to reduce the need for future surgery [20]
[21]. The data from studies of IOE for PJS support the benefit of regular surveillance,
in that no patients on the surveillance program developed polyp-related AEs requiring
emergency surgery. In 1995, IOE was accepted as a standard method to manage intestinal
hamartomas in patients with PJS [8].
The medical literature contains 19 previous studies describing experiences with DAE
for endoscopic removal of small-bowel hamartomas [15]
[16]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]. These articles vary significantly in regard to number of patients, geographic location,
and observation period. Belsha et al. followed a pediatric population in the United
States of 16 patients and demonstrated that DBE-facilitated polypectomy is an effective
therapeutic option in pediatric patients with PJS over 26 months [16]. The safety of DAE in prophylactic removal of hamartomas by DAE was described in
16 patients in Germany followed by two patients in Japan [22]
[23]
[24]. Gao et. al examined 13 patients over 356 combined patient months to concluded that
DBE is clinically useful and safe for diagnosis and therapy of small-bowel polyps
in patients with PJS and it may decrease the need for laparotomy [25]. These results were replicated by Akarsu et al (7 patients), Gorospe et al (22 patients),
Bizzari et al (10 patients), Torroni et al (6 patients) and Kroner et al (12 patients)
and Blanco-Velasso (4 patients) [26]
[27]
[28]
[29]
[30]
[31]
[32]. Kopacova et. al. also compared the efficacy of IOE with DAE in their cohort of
PJS patients in 2010 to demonstrate DAE to be as efficacious as IOE in the removal
of polyps and less morbid [33]. These studies attest to the capability and safety of DAE in removal of intestinal
hamartomas but most of these lack longer-term follow up with repeated DAE examinations
at scheduled intervals as evaluated in our study.
Of the 19 studies referenced above, six studies evaluated the use of DAE in an adult
PJS population and recorded surgical data similar to our study [13]
[28]
[34]
[35]
[36]
[37]. The findings of these studies are summarized in [Table 4]. Wang et. al [35] reported a significant decrease in size of hamartomas removed by DAE over an approximately
19-month average follow-up period. Mean polyp size on follow-up anterograde DAE decreased
from 36 mm to 21 mm while mean polyp size on retrograde DAE decreased from 3 mm to
1.2 mm. Following this report, Perrod et al. [36] published a retrospectice study of PJS patients registered in the Predisposition
Digestive Ile-de-France network. This study showed that DAE was successful in clearing
all polyps > 10 mm in the majority (76%) of patients with PJS. More recently, a retrospective
observational study published by Valdivia describes an Italian experience with DAE
in 23 PJS patients, of whom 22 were followed over an extended time frame (mean follow
up of 9 years). Only 9% of these patients required emergent surgery for AEs from small-bowel
hamartomas after index surveillance DAE compared with 27% prior to index surveillance
DAE. In all studies, there was a significant improvement in the rate of surgery after
initiation of small-bowel surveillance ([Table 4]).
Table 4 Data published on efficacy of DAE and rate of surgery.
References
|
No. patients
|
Observation time
|
DAE interval (years)
|
Procedure complication rate
|
Pre-enrollment surgery
|
Surgeries post-enrollment (during study period)
|
Summary of the data from studies published examining the efficacy of DAE on rate of
surgeries pre and post enrollment in study. We note the number of patients, study
time, interval DAE if applicable, procedure complication rate as well as pre- and
post-enrollment rate of surgery. DAE, device-assisted enteroscopy.
|
Wang et al.
|
97
|
46.7 (median)
|
2.5, 1.5
|
4.40%
|
57%
|
0
|
Perrod et al.
|
25
|
60 (median)
|
VCE or MRE 2–3
|
6%
|
64%
|
8%
|
Sakamoto et Al.
|
15
|
29.9 (mean)
|
Yearly
|
6.80%
|
86.70%
|
6%
|
Chen et al.
|
6
|
32 (mean)
|
1.66 ± 4 years AND 6–12 mo small-bowel series
|
0%
|
50%
|
0
|
Serrano et al.
|
25
|
56.5 (median)
|
NA
|
2.50%
|
74%
|
0
|
Valdivia et al.
|
24
|
108 (median)
|
NA
|
8.50%
|
66.7
|
9.10%
|
Our study provides similar data over an extended follow-up period with a diverse population
across the United States, thus building upon previous studies. We recognize that our
study also has limitations. The total number of subjects was small, which is expected
for such a rare disease. A retrospective design did not allow for prospective data
collection. The surveillance protocol utilized across the three study sites was similar
but not as uniform as would be found in a prospective trial with standardized management.
Conclusions
Our study shows that patients with PJS can be safely and effectively surveilled for
small-bowel hamartomas using DAE. This intervention should result in fewer laparotomies,
particularly emergent laparotomies, compared with historical management. We observed
a decrease in the rate of laparotomy from 75% to 8% over our study period after index
surveillance DAE with a mean surveillance interval of 2.5 years. We propose that patients
with PJS who have confirmed small-bowel hamartomas be surveilled in capable centers
by using DAE every 2 to 3 years, starting at the age of 18, to remove all hamartomas
≥ 10 mm. Removal of hamartomas using saline-lift combined with hot snare is recommended
as the single perforation observed in 131 polypectomies was observed in the setting
of hot snare resection alone.